N4P Share Price Performance
UK£0.0045
-0.00 (-14.29%)
Price UK£0.0045
Share PriceUK£0.0045
N4P Community Narratives
There are no narratives available yet.
Recent N4P News & Updates
No updates
N4 Pharma Plc Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0013
- Gross Margin
- 100.00%
- Net Profit Margin
- -14,537.52%
- Debt/Equity Ratio
- 0%
N4 Pharma Plc Competitors
About N4P
- Founded
- 1979
- Employees
- 4
- CEO
- WebsiteView website
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
U.K. Market Performance
- 7 Days: 0.3%
- 3 Months: 18.2%
- 1 Year: 16.0%
- Year to Date: 14.9%
In the last week, the market has been flat. More promisingly, the market is up 16% over the past year. As for the next few years, earnings are expected to grow by 13% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading